US-based biomedical research organisation CHDI Foundation and IBM Research have released a joint research paper revealing the development of a new artificial intelligence-based predictive model that ...
Combination anti-semaphorin 4D immunotherapy and ASO-mediated total HTT lowering provide benefit beyond either individual therapy in humanized HD mice To the extent that statements contained in this ...
HAMBURG, GERMANY / ACCESSWIRE / August 30, 2018 / Evotec AG (EVT.DE) (EVT.DE) (OTC PINK: EVTCY), (TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. ("CHDI") has extended its ...
CHDI, Inc. and Fisher BioImage ApS (BioImage) have announced that CHDI has licensed BioImage's Redistribution ® technology as a primary tool in its research and development efforts. CHDI will use ...
The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the official launch of C-Path's Huntington's Disease Regulatory Science Consortium (HD-RSC). In ...
GNS will use Big Data Analytics Technology to Unravel Underlying Biology of Huntington's Disease and Advance Discovery of New Treatments "GNS will apply its big data analytics platform to create a ...
Hamburg, Germany - 02 September 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. ("CHDI") has extended and expanded its ...
TUCSON, Arizona, October 31, 2016 -- Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly define regulatory pathways ...
Evotec AG have announced that CHDI Inc., a not-for profit organization pursuing a biotech approach to finding therapies for Huntington Disease, has chosen Evotec as a strategic partner for helping ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Hamburg, Germany - (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. ("CHDI") has extended and restated its collaboration with Evotec through 2017.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results